Literature DB >> 10747348

Genetic determinants of hemostasis phenotypes in Spanish families.

J C Souto1, L Almasy, M Borrell, M Garí, E Martínez, J Mateo, W H Stone, J Blangero, J Fontcuberta.   

Abstract

BACKGROUND: Recent studies have described genetic mutations that affect the risk of thrombosis as a result of abnormal levels of such hemostatic parameters as protein C, protein S, and the activated protein C resistance ratio. Although these mutations suggest that genes play a part in determining variability in some hemostasis-related phenotypes, the relative importance of genetic influences on these traits has not been evaluated. METHODS AND
RESULTS: The relative contributions of genetic and environmental influences to a panel of hemostasis-related phenotypes were assessed in a sample of 397 individuals in 21 extended pedigrees. The effects of measured covariates (sex, age, smoking, and exogenous sex hormones), genes, and environmental variables shared by members of a household were quantified for 27 hemostasis-related measures. All of these phenotypes showed significant genetic contributions, with the majority of heritabilities ranging between 22% and 55% of the residual phenotypic variance after correction for covariate effects. Activated protein C resistance ratio, activated partial thromboplastin time, and Factor XII showed the strongest heritabilities, with 71.3%, 83.0%, and 67.3%, respectively, of the residual phenotypic variation attributable to genetic effects.
CONCLUSIONS: These results clearly demonstrate the importance of genetic factors in determining variation in hemostasis-related phenotypes that are components of the coagulation and fibrinolysis pathways and that have been implicated in risk for thrombosis. The presence of such strong genetic effects suggests that it will be possible to localize previously unknown genes that influence quantitative variation in these hemostasis-related phenotypes that may contribute to risk for thrombosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10747348     DOI: 10.1161/01.cir.101.13.1546

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  58 in total

1.  Genetic associations for activated partial thromboplastin time and prothrombin time, their gene expression profiles, and risk of coronary artery disease.

Authors:  Weihong Tang; Christine Schwienbacher; Lorna M Lopez; Yoav Ben-Shlomo; Tiphaine Oudot-Mellakh; Andrew D Johnson; Nilesh J Samani; Saonli Basu; Martin Gögele; Gail Davies; Gordon D O Lowe; David-Alexandre Tregouet; Adrian Tan; James S Pankow; Albert Tenesa; Daniel Levy; Claudia B Volpato; Ann Rumley; Alan J Gow; Cosetta Minelli; John W G Yarnell; David J Porteous; John M Starr; John Gallacher; Eric Boerwinkle; Peter M Visscher; Peter P Pramstaller; Mary Cushman; Valur Emilsson; Andrew S Plump; Nena Matijevic; Pierre-Emmanuel Morange; Ian J Deary; Andrew A Hicks; Aaron R Folsom
Journal:  Am J Hum Genet       Date:  2012-06-14       Impact factor: 11.025

2.  Genome-wide association study identifies novel loci for plasma levels of protein C: the ARIC study.

Authors:  Weihong Tang; Saonli Basu; Xiaoxiao Kong; James S Pankow; Nena Aleksic; Adrian Tan; Mary Cushman; Eric Boerwinkle; Aaron R Folsom
Journal:  Blood       Date:  2010-08-27       Impact factor: 22.113

3.  Common variants of large effect in F12, KNG1, and HRG are associated with activated partial thromboplastin time.

Authors:  Lorna M Houlihan; Gail Davies; Albert Tenesa; Sarah E Harris; Michelle Luciano; Alan J Gow; Kevin A McGhee; David C Liewald; David J Porteous; John M Starr; Gordon D Lowe; Peter M Visscher; Ian J Deary
Journal:  Am J Hum Genet       Date:  2010-03-18       Impact factor: 11.025

4.  Mutations R67X and W303X of the protein Z-dependent protease inhibitor gene and venous thromboembolic disease: a case-control study in Italian subjects.

Authors:  Dora Fabbro; Giovanni Barillari; Giuseppe Damante
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

5.  A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.

Authors:  Kevin R Viel; Deepa K Machiah; Diane M Warren; Manana Khachidze; Alfonso Buil; Karl Fernstrom; Juan C Souto; Juan M Peralta; Todd Smith; John Blangero; Sandra Porter; Stephen T Warren; Jordi Fontcuberta; Jose M Soria; W Dana Flanders; Laura Almasy; Tom E Howard
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

6.  A quantitative-trait locus in the human factor XII gene influences both plasma factor XII levels and susceptibility to thrombotic disease.

Authors:  José Manuel Soria; Laura Almasy; Juan Carlos Souto; Delphine Bacq; Alfonso Buil; Alexandra Faure; Elisabeth Martínez-Marchán; José Mateo; Montserrat Borrell; William Stone; Mark Lathrop; Jordi Fontcuberta; John Blangero
Journal:  Am J Hum Genet       Date:  2002-01-22       Impact factor: 11.025

7.  Genetic variants associated with protein C levels.

Authors:  C Y Vossen; B P Koeleman; S J Hasstedt; I J Nijman; I J Renkens; P W Callas; F R Rosendaal; E G Bovill
Journal:  J Thromb Haemost       Date:  2013-04       Impact factor: 5.824

8.  Genome-wide linkage analysis for identifying quantitative trait loci involved in the regulation of lipoprotein a (Lpa) levels.

Authors:  Sonia López; Alfonso Buil; Jordi Ordoñez; Juan Carlos Souto; Laura Almasy; Mark Lathrop; John Blangero; Francisco Blanco-Vaca; Jordi Fontcuberta; José Manuel Soria
Journal:  Eur J Hum Genet       Date:  2008-06-18       Impact factor: 4.246

9.  A genome-wide exploration suggests an oligogenic model of inheritance for the TAFI activity and its antigen levels.

Authors:  Maria Sabater-Lleal; Alfonso Buil; Juan Carlos Souto; Laura Alamsy; Montserrat Borrell; Mark Lathrop; John Blangero; Jordi Fontcuberta; José Manuel Soria
Journal:  Hum Genet       Date:  2008-06-18       Impact factor: 4.132

10.  Combined cis-regulator elements as important mechanism affecting FXII plasma levels.

Authors:  Maria Sabater-Lleal; Miguel Chillón; Carolina Mordillo; Angel Martínez; Estel Gil; José Mateo; John Blangero; Laura Almasy; Jordi Fontcuberta; José Manuel Soria
Journal:  Thromb Res       Date:  2009-09-27       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.